You are using an outdated browser. Please upgrade your browser to improve your experience.

Our Focus

Chiasma is a biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop and ultimately commercialize oral medications that are currently only available as injections. The company is developing octreotide capsules (conditionally trade named Mycapssa®) for the potential maintenance treatment of adults with acromegaly.